Exozymes (EXOZ) Net Income towards Common Stockholders Growth (1y) (2024 - 2026)

Exozymes (EXOZ) Net Income towards Common Stockholders Growth (1y) (2024 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income Growth (1y) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	6.48%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-6.81%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	92.37%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	5.21%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	151.28%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	327.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-147.59%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	95.87%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-12.04%
10	Exozymes	62.35 Mn	62.35 Mn	-	-

Download Data